Stock Analysis on Net
Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Common-Size Income Statement
Quarterly Data

Thermo Fisher Scientific Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021 Dec 31, 2020 Sep 26, 2020 Jun 27, 2020 Mar 28, 2020 Dec 31, 2019 Sep 28, 2019 Jun 29, 2019 Mar 30, 2019
Product revenues 57.56 58.89 58.23 58.68 59.79 60.66 61.66 63.84 67.84 74.11 78.89 77.80 79.31 81.93 79.59 75.90 74.32 75.43 76.50 76.42 77.06
Service revenues 42.44 41.11 41.77 41.32 40.21 39.34 38.34 36.16 32.16 25.89 21.11 22.20 20.69 18.07 20.41 24.10 25.68 24.57 23.50 23.58 22.94
Revenues 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of product revenues -28.41 -30.67 -30.40 -30.67 -31.16 -32.16 -32.72 -32.05 -30.08 -33.80 -35.35 -36.15 -33.59 -34.83 -35.22 -34.57 -37.56 -39.16 -39.40 -39.23 -39.41
Cost of service revenues -30.94 -28.97 -28.79 -29.55 -30.19 -27.62 -26.98 -26.03 -23.68 -17.11 -14.80 -15.07 -13.83 -12.50 -13.95 -16.61 -18.46 -16.40 -16.55 -16.07 -16.39
Cost of revenues -59.35% -59.65% -59.18% -60.22% -61.34% -59.77% -59.71% -58.08% -53.77% -50.91% -50.15% -51.21% -47.42% -47.34% -49.17% -51.18% -56.02% -55.56% -55.95% -55.30% -55.80%
Gross profit 40.65% 40.35% 40.82% 39.78% 38.66% 40.23% 40.29% 41.92% 46.23% 49.09% 49.85% 48.79% 52.58% 52.66% 50.83% 48.82% 43.98% 44.44% 44.05% 44.70% 44.20%
Selling, general and administrative expenses -21.10 -19.58 -19.38 -20.07 -19.79 -20.08 -20.68 -20.14 -19.27 -21.29 -21.48 -20.48 -18.43 -19.69 -18.68 -24.72 -24.90 -22.14 -24.54 -24.78 -24.95
Research and development expenses -3.20 -3.00 -3.02 -3.23 -3.23 -3.41 -3.29 -3.33 -3.08 -3.66 -3.76 -3.70 -3.23 -3.56 -3.47 -3.82 -3.93 -3.84 -3.94 -3.89 -4.05
Restructuring and other income (costs) -0.27 -0.73 -0.79 -1.71 -1.05 -0.48 -0.31 -0.22 -0.02 -0.43 -0.19 -1.28 -0.14 -0.30 -0.20 -0.17 -0.61 -0.42 -0.49 7.66 -0.18
Operating income 16.08% 17.03% 17.63% 14.77% 14.59% 16.25% 16.02% 18.24% 23.87% 23.72% 24.42% 23.33% 30.78% 29.11% 28.47% 20.11% 14.54% 18.04% 15.08% 23.69% 15.02%
Interest income 2.70 2.84 2.33 1.67 1.36 1.31 0.64 0.33 0.15 0.10 0.10 0.12 0.12 0.11 0.11 0.12 0.58 0.66 0.83 0.95 1.09
Interest expense -3.51 -3.58 -3.40 -3.05 -2.80 -2.35 -1.62 -1.35 -1.15 -1.50 -1.37 -1.32 -1.26 -1.38 -1.69 -1.98 -2.02 -2.08 -2.61 -2.87 -3.09
Other income (expense) 0.10 -0.30 0.13 0.00 -0.43 0.31 -0.04 0.26 -1.38 -4.91 0.19 -0.03 -1.85 -0.43 -0.46 -0.13 0.19 -1.42 -0.19 0.28 0.31
Income from continuing operations before income taxes 15.36% 15.98% 16.69% 13.38% 12.73% 15.52% 14.99% 17.47% 21.49% 17.40% 23.33% 22.10% 27.79% 27.41% 26.43% 18.11% 13.29% 15.20% 13.11% 22.06% 13.34%
Provision for income taxes -2.72 -1.22 -0.50 -0.49 -0.43 -1.51 -0.29 -1.80 -2.55 -1.90 -2.90 -2.36 -4.20 -3.73 -3.74 -1.40 -0.64 -0.53 -0.99 -4.34 -0.03
Equity in earnings (losses) of unconsolidated entities 0.22 -0.01 -0.16 -0.15 -0.23 -0.26 -0.67 -0.46 -0.16 0.00 -0.03 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income 12.87% 14.75% 16.03% 12.74% 12.06% 13.75% 14.03% 15.21% 18.78% 15.50% 20.40% 19.72% 23.59% 23.68% 22.69% 16.71% 12.65% 14.67% 12.12% 17.72% 13.31%
Net (income) losses attributable to noncontrolling interests and redeemable noncontrolling interest -0.03 0.22 0.19 -0.01 -0.03 0.02 -0.03 -0.04 -0.04 -0.01 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income attributable to Thermo Fisher Scientific Inc. 12.84% 14.97% 16.22% 12.74% 12.04% 13.76% 14.00% 15.17% 18.74% 15.49% 20.39% 19.71% 23.59% 23.68% 22.69% 16.71% 12.65% 14.67% 12.12% 17.72% 13.31%

Based on: 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).

Income statement item Description The company
Operating income The net result for the period of deducting operating expenses from operating revenues. Thermo Fisher Scientific Inc. operating income as a percentage of revenues decreased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.
Income from continuing operations before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Thermo Fisher Scientific Inc. income from continuing operations before income taxes as a percentage of revenues decreased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.
Net income attributable to Thermo Fisher Scientific Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Thermo Fisher Scientific Inc. net income attributable to Thermo Fisher Scientific Inc. as a percentage of revenues decreased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024.